Crescent Biopharma, Inc.
Crescent Biopharma, Inc. (CBIO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cbio · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Crescent Biopharma, Inc. (CBIO) measures how much investors pay for each dollar of the company's trailing earnings. CBIO's current PE ratio of N/A is calculated by dividing its stock price of $18.15 by its TTM earnings per share of -$5.33.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Crescent Biopharma, Inc.You CBIO | $500M | N/A | — | -$5.33 |
 Armata Pharmaceuticals, Inc. ARMP | $274M | N/A | — | -$4.80 |
 C4 Therapeutics, Inc. CCCC | $309M | N/A | — | -$1.27 |
 Compugen Ltd. CGEN | $197M | 4.04x | — | $0.38 |
 Vyome Holdings, Inc. HIND | $13M | N/A | — | -$4.75 |
 Heron Therapeutics, Inc. HRTX | $71M | N/A | — | -$0.12 |
 Insight Molecular Diagnostics Inc. IMDX | $161M | N/A | — | -$1.65 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-14.78 | — | |
2024-12-31 FY2024 | — | $-2.49 | — | |
2023-12-31 FY2023 | — | $-0.58 | — | |
2022-12-31 FY2022 | — | $-0.89 | — | |
2021-12-31 FY2021 | — | $-1.23 | — | |
2020-12-31 FY2020 | — | $-1.12 | — | |
2019-12-31 FY2019 | — | $-1.25 | — | |
2018-12-31 FY2018 | — | $-1.18 | — | |
2017-12-31 FY2017 | — | $-1.13 | — | |
2016-12-31 FY2016 | — | $-1.50 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Crescent Biopharma, Inc. (CBIO) measures how much investors pay for each dollar of the company's trailing earnings. CBIO's current PE ratio of N/A is calculated by dividing its stock price of $18.15 by its TTM earnings per share of -$5.33.
Frequently asked questions
CBIO pe ratio · 6 questionsCBIO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $18.15 and TTM EPS of -$5.33. Data sourced from Financial Modeling Prep via CBIO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Crescent Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09